共 152 条
[21]
Babineaux SM(2012)Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register Arthritis Care Res (Hoboken) 64 1108-473
[22]
Curtis B(2016)Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis J Med Econ 19 91-1952
[23]
Holbrook T(2016)Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication Clinicoecon Outcomes Res 8 707-1180
[24]
Milligan G(2017)Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis J Med Econ 20 464-1793
[25]
Piercy J(2017)Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: real-world observational study of rheumatoid arthritis patients in the united states with prior tumor necrosis factor inhibitor therapy Adv Ther 34 1936-670
[26]
Anderson P(2016)Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial JAMA 316 1172-290
[27]
Benford M(2015)Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry Clin Rheumatol 34 1787-575
[28]
Harris N(2014)Comparative effectiveness of cycling of tumor necrosis factor-alpha (TNF-alpha) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-alpha inhibitor using a Bayesian approach Arch Pharm Res 37 662-324
[29]
Karavali M(2015)Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry Arthritis Res Ther 17 256-undefined
[30]
Piercy J(2002)Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy Arthritis Rheum 47 285-undefined